73 related articles for article (PubMed ID: 36736884)
21. A Broad-Spectrum Inhibitor of CRISPR-Cas9.
Harrington LB; Doxzen KW; Ma E; Liu JJ; Knott GJ; Edraki A; Garcia B; Amrani N; Chen JS; Cofsky JC; Kranzusch PJ; Sontheimer EJ; Davidson AR; Maxwell KL; Doudna JA
Cell; 2017 Sep; 170(6):1224-1233.e15. PubMed ID: 28844692
[TBL] [Abstract][Full Text] [Related]
22. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
[TBL] [Abstract][Full Text] [Related]
23. Structural and Mechanistic Insight into CRISPR-Cas9 Inhibition by Anti-CRISPR Protein AcrIIC4
Hwang S; Pan C; Garcia B; Davidson AR; Moraes TF; Maxwell KL
J Mol Biol; 2022 Mar; 434(5):167420. PubMed ID: 34954237
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potent and versatile CRISPR-Cas9 inhibitors engineered for chemically controllable genome editing.
Song G; Zhang F; Tian C; Gao X; Zhu X; Fan D; Tian Y
Nucleic Acids Res; 2022 Mar; 50(5):2836-2853. PubMed ID: 35188577
[TBL] [Abstract][Full Text] [Related]
25. The CRISPR/Cas system in Neisseria meningitidis affects bacterial adhesion to human nasopharyngeal epithelial cells.
Heidrich N; Hagmann A; Bauriedl S; Vogel J; Schoen C
RNA Biol; 2019 Apr; 16(4):390-396. PubMed ID: 30059276
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for the promiscuous PAM recognition by Corynebacterium diphtheriae Cas9.
Hirano S; Abudayyeh OO; Gootenberg JS; Horii T; Ishitani R; Hatada I; Zhang F; Nishimasu H; Nureki O
Nat Commun; 2019 Apr; 10(1):1968. PubMed ID: 31036811
[TBL] [Abstract][Full Text] [Related]
27. [Type II CRISPR-Cas System Nucleases: A Pipeline for Prediction and In Vitro Characterization].
Vasileva AA; Aliukas SA; Selkova PA; Arseniev AN; Chernova VE; Musharova OS; Klimuk EI; Khodorkovskii MA; Severinov KV
Mol Biol (Mosk); 2023; 57(3):546-560. PubMed ID: 37326060
[TBL] [Abstract][Full Text] [Related]
28. Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing.
Garcia B; Lee J; Edraki A; Hidalgo-Reyes Y; Erwood S; Mir A; Trost CN; Seroussi U; Stanley SY; Cohn RD; Claycomb JM; Sontheimer EJ; Maxwell KL; Davidson AR
Cell Rep; 2019 Nov; 29(7):1739-1746.e5. PubMed ID: 31722192
[TBL] [Abstract][Full Text] [Related]
29. Critical Anti-CRISPR Locus Repression by a Bi-functional Cas9 Inhibitor.
Osuna BA; Karambelkar S; Mahendra C; Sarbach A; Johnson MC; Kilcher S; Bondy-Denomy J
Cell Host Microbe; 2020 Jul; 28(1):23-30.e5. PubMed ID: 32325051
[TBL] [Abstract][Full Text] [Related]
30. SpRY Cas9 Can Utilize a Variety of Protospacer Adjacent Motif Site Sequences To Edit the Candida albicans Genome.
Evans BA; Bernstein DA
mSphere; 2021 May; 6(3):. PubMed ID: 34011687
[No Abstract] [Full Text] [Related]
31. Optogenetic control of Neisseria meningitidis Cas9 genome editing using an engineered, light-switchable anti-CRISPR protein.
Hoffmann MD; Mathony J; Upmeier Zu Belzen J; Harteveld Z; Aschenbrenner S; Stengl C; Grimm D; Correia BE; Eils R; Niopek D
Nucleic Acids Res; 2021 Mar; 49(5):e29. PubMed ID: 33330940
[TBL] [Abstract][Full Text] [Related]
32. Modulating CRISPR/Cas9 genome-editing activity by small molecules.
Chen S; Chen D; Liu B; Haisma HJ
Drug Discov Today; 2022 Apr; 27(4):951-966. PubMed ID: 34823004
[TBL] [Abstract][Full Text] [Related]
33. Allosteric inhibition of CRISPR-Cas9 by bacteriophage-derived peptides.
Cui YR; Wang SJ; Chen J; Li J; Chen W; Wang S; Meng B; Zhu W; Zhang Z; Yang B; Jiang B; Yang G; Ma P; Liu J
Genome Biol; 2020 Feb; 21(1):51. PubMed ID: 32102684
[TBL] [Abstract][Full Text] [Related]
34. Protein Inhibitors of CRISPR-Cas9.
Bondy-Denomy J
ACS Chem Biol; 2018 Feb; 13(2):417-423. PubMed ID: 29251498
[TBL] [Abstract][Full Text] [Related]
35. A CRISPR-Cas9-integrase complex generates precise DNA fragments for genome integration.
Jakhanwal S; Cress BF; Maguin P; Lobba MJ; Marraffini LA; Doudna JA
Nucleic Acids Res; 2021 Apr; 49(6):3546-3556. PubMed ID: 33693715
[TBL] [Abstract][Full Text] [Related]
36. Use of anti-CRISPR protein AcrIIA4 as a capture ligand for CRISPR/Cas9 detection.
Johnston RK; Seamon KJ; Saada EA; Podlevsky JD; Branda SS; Timlin JA; Harper JC
Biosens Bioelectron; 2019 Sep; 141():111361. PubMed ID: 31207570
[TBL] [Abstract][Full Text] [Related]
37. The novel anti-CRISPR AcrIIA22 relieves DNA torsion in target plasmids and impairs SpyCas9 activity.
Forsberg KJ; Schmidtke DT; Werther R; Uribe RV; Hausman D; Sommer MOA; Stoddard BL; Kaiser BK; Malik HS
PLoS Biol; 2021 Oct; 19(10):e3001428. PubMed ID: 34644300
[TBL] [Abstract][Full Text] [Related]
38. Search and Localization Dynamics of the CRISPR-Cas9 System.
Lu Q; Bhat D; Stepanenko D; Pigolotti S
Phys Rev Lett; 2021 Nov; 127(20):208102. PubMed ID: 34860046
[TBL] [Abstract][Full Text] [Related]
39. PAM-Dependent Target DNA Recognition and Cleavage by C2c1 CRISPR-Cas Endonuclease.
Yang H; Gao P; Rajashankar KR; Patel DJ
Cell; 2016 Dec; 167(7):1814-1828.e12. PubMed ID: 27984729
[TBL] [Abstract][Full Text] [Related]
40. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems.
Fonfara I; Le Rhun A; Chylinski K; Makarova KS; Lécrivain AL; Bzdrenga J; Koonin EV; Charpentier E
Nucleic Acids Res; 2014 Feb; 42(4):2577-90. PubMed ID: 24270795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
